GrippeAllemagneV3, Main, Exploration, bibRecord, 000071

[Influenza: Whats new?]

Identifieur interne : 000071 ( Main/Exploration ); précédent : 000070; suivant : 000072

[Influenza: Whats new?]

Auteurs : Bernd Salzberger ; Barbara Schmidt

Source :

Deutsche medizinische Wochenschrift (1946) [ 1439-4413 ] ; 2016.

RBID : pubmed:27701689

Descripteurs français

KwdFr :
- Allemagne (épidémiologie), Facteurs de risque, Flambées de maladies (), Grippe humaine (), Grippe humaine (diagnostic), Grippe humaine (épidémiologie), Humains, Prévalence, Résultat thérapeutique, Sialidase (antagonistes et inhibiteurs), Surveillance de la population (), Vaccination de masse (), Vaccins antigrippaux (administration et posologie).
MESH :
- administration et posologie : Vaccins antigrippaux.
- antagonistes et inhibiteurs : Sialidase.
- diagnostic : Grippe humaine.
- épidémiologie : Allemagne, Grippe humaine.
- Facteurs de risque, Flambées de maladies, Grippe humaine, Humains, Prévalence, Résultat thérapeutique, Surveillance de la population, Vaccination de masse.

English descriptors

KwdEn :
- Disease Outbreaks (prevention & control), Disease Outbreaks (statistics & numerical data), Germany (epidemiology), Humans, Influenza Vaccines (administration & dosage), Influenza, Human (diagnosis), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Mass Vaccination (statistics & numerical data), Neuraminidase (antagonists & inhibitors), Population Surveillance (methods), Prevalence, Risk Factors, Treatment Outcome.
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , antagonists & inhibitors : Neuraminidase.
- diagnosis : Influenza, Human.
- epidemiology : Germany, Influenza, Human.
- methods : Population Surveillance.
- prevention & control : Disease Outbreaks, Influenza, Human.
- statistics & numerical data : Disease Outbreaks, Mass Vaccination.
- Humans, Prevalence, Risk Factors, Treatment Outcome.

Abstract

The burden of disease of influenza in Germany has been dominated by high rates of complications in elderly patients in years with high circulation of H3N2 viruses after the introduction of the new H1N1 strain in 2009. Human infections with avian influenza viruses occur mostly in China. Due to the potential of reassortment with human strains these cases are monitored closely. The efficacy of neuraminidase inhibitors (NI) has been newly rated. In randomized studies effects on reduction of complications could not be found, although large cohort studies have demonstrated a reduction of mortality in patients treated with vs. without neuraminidase inhibitors.The administration and acceptance of influenza vaccine is low in Germany in general and in risk populations. New vaccines have been introduced with quadrivalent vaccines covering both circulating B-types simultaneously and high dose vaccines for elder patients.

DOI: 10.1055/s-0042-108538
PubMed: 27701689

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000075
to stream Main, to step Curation: 000075

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Influenza: Whats new?]</title>
<author><name sortKey="Salzberger, Bernd" sort="Salzberger, Bernd" uniqKey="Salzberger B" first="Bernd" last="Salzberger">Bernd Salzberger</name>
</author>
<author><name sortKey="Schmidt, Barbara" sort="Schmidt, Barbara" uniqKey="Schmidt B" first="Barbara" last="Schmidt">Barbara Schmidt</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27701689</idno>
<idno type="pmid">27701689</idno>
<idno type="doi">10.1055/s-0042-108538</idno>
<idno type="wicri:Area/Main/Corpus">000075</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000075</idno>
<idno type="wicri:Area/Main/Curation">000075</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000075</idno>
<idno type="wicri:Area/Main/Exploration">000075</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Influenza: Whats new?]</title>
<author><name sortKey="Salzberger, Bernd" sort="Salzberger, Bernd" uniqKey="Salzberger B" first="Bernd" last="Salzberger">Bernd Salzberger</name>
</author>
<author><name sortKey="Schmidt, Barbara" sort="Schmidt, Barbara" uniqKey="Schmidt B" first="Barbara" last="Schmidt">Barbara Schmidt</name>
</author>
</analytic>
<series><title level="j">Deutsche medizinische Wochenschrift (1946)</title>
<idno type="eISSN">1439-4413</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Disease Outbreaks (prevention & control)</term>
<term>Disease Outbreaks (statistics & numerical data)</term>
<term>Germany (epidemiology)</term>
<term>Humans</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza, Human (diagnosis)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Mass Vaccination (statistics & numerical data)</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Population Surveillance (methods)</term>
<term>Prevalence</term>
<term>Risk Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne (épidémiologie)</term>
<term>Facteurs de risque</term>
<term>Flambées de maladies ()</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (diagnostic)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Prévalence</term>
<term>Résultat thérapeutique</term>
<term>Sialidase (antagonistes et inhibiteurs)</term>
<term>Surveillance de la population ()</term>
<term>Vaccination de masse ()</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Germany</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Population Surveillance</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Disease Outbreaks</term>
<term>Mass Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Prevalence</term>
<term>Risk Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term>
<term>Flambées de maladies</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Prévalence</term>
<term>Résultat thérapeutique</term>
<term>Surveillance de la population</term>
<term>Vaccination de masse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The burden of disease of influenza in Germany has been dominated by high rates of complications in elderly patients in years with high circulation of H3N2 viruses after the introduction of the new H1N1 strain in 2009. Human infections with avian influenza viruses occur mostly in China. Due to the potential of reassortment with human strains these cases are monitored closely. The efficacy of neuraminidase inhibitors (NI) has been newly rated. In randomized studies effects on reduction of complications could not be found, although large cohort studies have demonstrated a reduction of mortality in patients treated with vs. without neuraminidase inhibitors.The administration and acceptance of influenza vaccine is low in Germany in general and in risk populations. New vaccines have been introduced with quadrivalent vaccines covering both circulating B-types simultaneously and high dose vaccines for elder patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27701689</PMID>
<DateCompleted><Year>2017</Year>
<Month>03</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-4413</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>141</Volume>
<Issue>20</Issue>
<PubDate><Year>2016</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Deutsche medizinische Wochenschrift (1946)</Title>
<ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation>
</Journal>
<ArticleTitle>[Influenza: Whats new?]</ArticleTitle>
<Pagination><MedlinePgn>1451-1454</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The burden of disease of influenza in Germany has been dominated by high rates of complications in elderly patients in years with high circulation of H3N2 viruses after the introduction of the new H1N1 strain in 2009. Human infections with avian influenza viruses occur mostly in China. Due to the potential of reassortment with human strains these cases are monitored closely. The efficacy of neuraminidase inhibitors (NI) has been newly rated. In randomized studies effects on reduction of complications could not be found, although large cohort studies have demonstrated a reduction of mortality in patients treated with vs. without neuraminidase inhibitors.The administration and acceptance of influenza vaccine is low in Germany in general and in risk populations. New vaccines have been introduced with quadrivalent vaccines covering both circulating B-types simultaneously and high dose vaccines for elder patients.</AbstractText>
<CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salzberger</LastName>
<ForeName>Bernd</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schmidt</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Neues zur Influenza.</VernacularTitle>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>10</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Dtsch Med Wochenschr</MedlineTA>
<NlmUniqueID>0006723</NlmUniqueID>
<ISSNLinking>0012-0472</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>10</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>10</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>3</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27701689</ArticleId>
<ArticleId IdType="doi">10.1055/s-0042-108538</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Salzberger, Bernd" sort="Salzberger, Bernd" uniqKey="Salzberger B" first="Bernd" last="Salzberger">Bernd Salzberger</name>
<name sortKey="Schmidt, Barbara" sort="Schmidt, Barbara" uniqKey="Schmidt B" first="Barbara" last="Schmidt">Barbara Schmidt</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000071 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000071 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeAllemagneV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27701689
   |texte=   [Influenza: Whats new?]
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27701689" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 11:47:10 2020. Site generation: Sat Sep 26 09:55:33 2020

	Corpus GrippeAllemagneV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeAllemagneV3

[Influenza: Whats new?]

[Influenza: Whats new?]

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki